An Interpretable Multitask Framework BiLAT Enables Accurate Prediction of Cyclin-Dependent Protein Kinase Inhibitors

被引:5
|
作者
Qian, Xu [1 ]
Dai, Xiaowen [1 ]
Luo, Lin [1 ]
Lin, Mingde [1 ]
Xu, Yuan [1 ]
Zhao, Yang [1 ]
Huang, Dingfang [1 ]
Qiu, Haodi [1 ]
Liang, Li [1 ]
Liu, Haichun [1 ]
Liu, Yingbo [1 ]
Gu, Lingxi [1 ]
Lu, Tao [1 ,2 ]
Chen, Yadong [1 ]
Zhang, Yanmin [1 ]
机构
[1] China Pharmaceut Univ, Sch Sci, Lab Mol Design & Drug Discovery, Nanjing 211198, Peoples R China
[2] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
CELL-CYCLE; CANCER; TARGETS; CDKS;
D O I
10.1021/acs.jcim.3c00473
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The cyclin-dependent protein kinases (CDKs) are protein-serine/threonine kinases with crucial effects on the regulation of cell cycle and transcription. CDKs can be a hallmark of cancer since their excessive expression could lead to impaired cell proliferation. However, the selectivity profile of most developed CDK inhibitors is not enough, which have hindered the therapeutic use of CDK inhibitors. In this study, we propose a multitask deep learning framework called BiLAT based on SMILES representation for the prediction of the inhibitory activity of molecules on eight CDK subtypes (CDK1, 2, 4-9). The framework is mainly composed of an improved bidirectional long short-term memory module BiLSTM and the encode layer of the Transformer framework. Additionally, the data enhancement method of SMILES enumeration is applied to improve the performance of the model. Compared with baseline predictive models based on three conventional machine learning methods and two multitask deep learning algorithms, BiLAT achieves the best performance with the highest average AUC, ACC, F1-score, and MCC values of 0.938, 0.894, 0.911, and 0.715 for the test set. Moreover, we constructed a targeted external data set CDK-Dec for the CDK family, which mainly contains bait values screened by 3D similarity with active compounds. This dataset was utilized in the subsequent evaluation of our model. It is worth mentioning that the BiLAT model is interpretable and can be used by chemists to design and synthesize compounds with improved activity. To further verify the generalization ability of the multitask BiLAT model, we also conducted another evaluation on three public datasets (Tox21, ClinTox, and SIDER). Compared with several currently popular models, BiLAT shows the best performance on two datasets. These results indicate that BiLAT is an effective tool for accelerating drug discovery.
引用
收藏
页码:3350 / 3368
页数:19
相关论文
共 50 条
  • [41] Cyclin-dependent kinase inhibitors: novel anticancer agents
    Mani, S
    Wang, CG
    Wu, KM
    Francis, R
    Pestell, R
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) : 1849 - 1870
  • [42] Cyclin-dependent kinase 7 inhibitors in cancer therapy
    Wang, Minmin
    Wang, Tianyu
    Zhang, Xiangyu
    Wu, Xiaoxing
    Jiang, Sheng
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (09) : 813 - 833
  • [43] Cyclin-dependent kinase inhibitors move into Phase III
    Guha, Malini
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (12) : 892 - 894
  • [44] Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies
    Baghdassarian, N
    Ffrench, M
    HEMATOLOGY AND CELL THERAPY, 1996, 38 (04): : 313 - 323
  • [45] Cyclin-dependent kinase inhibitors for the treatment of lung cancer
    Qin, Angel
    Reddy, Haritha G.
    Weinberg, Frank D.
    Kalemkerian, Gregory P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (08) : 941 - 952
  • [46] Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2
    Johnson, LN
    De Moliner, E
    Brown, NR
    Song, HW
    Barford, D
    Endicott, JA
    Noble, MEM
    PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) : 113 - 124
  • [47] Genetic Framework of Cyclin-Dependent Kinase Function in Arabidopsis
    Nowack, Moritz K.
    Harashima, Hirofumi
    Dissmeyer, Nico
    Zhao, Xin'Ai
    Bouyer, Daniel
    Weimer, Annika K.
    De Winter, Freya
    Yang, Fang
    Schnittger, Arp
    DEVELOPMENTAL CELL, 2012, 22 (05) : 1030 - 1040
  • [48] PRECLINICAL AND CLINICAL DEVELOPMENT OF CYCLIN-DEPENDENT KINASE AND CHECKPOINT KINASE INHIBITORS
    Shapiro, G. I.
    ANNALS OF ONCOLOGY, 2010, 21 : 27 - 27
  • [49] Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma
    Ramakrishnan, Vijay G.
    Kumar, Shaji K.
    CANCER JOURNAL, 2016, 22 (01): : 7 - 11
  • [50] Structural characterization of the cyclin-dependent protein kinase family
    Endicott, Jane A.
    Noble, Martin E. M.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2013, 41 : 1008 - 1016